NCT00910858 - A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

May 31, 2009

Conditions

Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

Interventions

DRUG

Lenalidomide

Lenalidomide 5-mg capsules for oral administration

DRUG

Recombinant human erythropoietin

Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.

Trial Locations (1)

H. Lee Moffitt Cancer Center and Research Institute, Tampa